Microfluidic biosensing platform based on up-conversion luminescence
By upconverting the luminescent microfluidic biosensing platform and aptamer-mediated nanoparticle bridging flocculation phenomenon, the expensive equipment and background interference problems of existing EDCs detection methods are solved, and the rapid, sensitive and quantitative detection of EDCs is achieved. , suitable for field applications.
Patent Information
- Application Number
- PCT/CN2023/096734
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2023-05-29
- Publication Date
- 2024-11-28
AI Technical Summary
The existing EDCs detection methods have problems such as expensive detection instruments and equipment, strong background interference, cumbersome sample pretreatment steps, and large reagent consumption, making it difficult to achieve rapid on-site quantitative detection of EDCs.
Using an upconversion luminescence-based microfluidic biosensing platform, the microsampling and high-sensitive quantitative detection of EDCs is achieved through the integration of upconversion luminescence biosensors and microfluidic chips, and the nanoparticle bridge flocculation is used to utilize aptamer-mediated nanoparticle bridged flocculation. The phenomenon enhances the fluorescent signal, combining the mixing, reaction, separation and detection functions of the microfluidic chip.
It realizes fast, sensitive and quantitative detection of EDCs, improves detection limits and signal stability, simplifies sample processing steps, reduces detection costs, and is suitable for field applications.
Smart Images

Figure CN2023096734_28112024_PF_FP_ABST
Abstract
Description
A microfluidic biosensing platform based on upconversion luminescence Technical Field
[0001] The present invention relates to the technical field of food safety detection, and in particular to a microfluidic biosensor platform based on up-conversion luminescence. Background Art
[0002] Endocrine disrupting chemicals (EDCs) are defined as "exogenous agents that interfere with the synthesis, secretion, transport, metabolism, binding or elimination of natural blood-derived hormones in the human body that are responsible for balance, reproduction and developmental processes." Humans may ingest hundreds of EDCs through food production (food additives, pesticides, food containers), industrial activities (air pollution, water pollutants, industrial chemicals), medical treatment (medical products), etc. Among them, exogenous agents with estrogenic effects, such as bisphenol A (BPA), diethylstilbestrol (DES), estradiol (E2), nonylphenol, etc. have attracted widespread attention. These EDCs may cause serious health hazards, including neurodevelopmental disorders, brain, liver and lung damage, reproductive and endocrine disorders, metabolic disorders, etc. Therefore, it is very important to establish an effective assessment method to determine the content of EDCs in media that humans may be exposed to.
[0003] Previous studies have used methods such as high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), electrochemical sensors, and photoelectrochemical immunosensors to determine EDCs. However, these methods often face challenges such as expensive instrumentation, strong background interference, cumbersome sample pretreatment, and high reagent consumption, making rapid, on-site quantitative detection of EDCs difficult. Therefore, developing novel detection platforms to overcome these limitations is crucial.
[0004] Summary of the Invention
[0005] In view of the shortcomings of the existing technology, the present invention provides a microfluidic biosensing platform based on upconversion luminescence to achieve microsampling and simple high-sensitivity quantitative detection of EDCs.
[0006] Based on this, the purpose of the present invention is to provide a microfluidic biosensor platform based on upconversion luminescence, comprising: an upconversion luminescence biosensor for specifically identifying EDCs; and a microfluidic chip as a reaction platform between the upconversion luminescence biosensor and the sample to be tested, for integrating the mixing, reaction, separation, and detection of the upconversion luminescence biosensor and the sample to be tested;
[0007] The microfluidic chip includes: an injection pool for injecting the upconversion luminescence biosensor and the sample to be tested; an arcuate channel, the feed port of which is simultaneously connected to the injection pool of the upconversion luminescence biosensor and the sample to be tested. After the upconversion luminescence biosensor and the sample to be tested enter the arcuate channel, the arcuate channel is used for mixing and reacting the two; a separation channel, which is connected to the discharge port of the arcuate channel and is used for magnetic separation of the upconversion luminescence biosensor after the reaction is completed; and a detection pool, which is connected to the discharge port of the separation channel and is used for luminescence-enhanced quantitative detection of EDCs.
[0008] Furthermore, all microchannels of the microfluidic chip have a width of 400 μm and a depth of 200 μm.
[0009] According to the above technical solution, the mixing, reaction, separation and detection of the upconversion luminescence biosensor and the sample to be tested are integrated on the microfluidic chip. The specific process is: the upconversion luminescence biosensor and the sample to be tested are respectively injected from the two sampling pools of the microfluidic chip, and the two microfluids are fully mixed and reacted in the arc channel; then, an external magnetic field is applied at the separation channel to separate the biosensor that has not reacted with EDCs; finally, in the detection pool, the detached CSUCNPs complete bridging flocculation and sedimentation, and the upconversion fluorescence signal is collected, so that EDCs can be quantitatively detected.
[0010] Furthermore, the injection flow rates of the biosensor and the sample solution to be tested are 12 μL / min and 3 μL / min.
[0011] Furthermore, the injection time between the biosensor and the sample solution to be tested is 8-12 minutes.
[0012] The second object of the present invention is to provide a method for preparing the above-mentioned microfluidic biosensing platform based on upconversion luminescence.
[0013] The preparation method of the upconversion luminescence biosensor comprises the following steps:
[0014] S1. Preparation of upconversion nanoparticle seeds containing rare earth elements (CUCNPs);
[0015] S2, coating the outer layer of the CUCNPs prepared in step S1 to prepare upconversion nanoparticles (CSUCNPs) with a core-shell structure;
[0016] S3, the CSUCNPs prepared in the modification step S2 are hydrophilic;
[0017] S4, functionalizing the hydrophilic CSUCNPs obtained in step S3 with biomolecules to obtain biomolecule-functionalized CSUCNPs;
[0018] S5. Preparation of magnetic nanoparticles (MNPs);
[0019] S6, functionalizing the MNPs obtained in step S5 with biomolecules to obtain biomolecule-functionalized MNPs;
[0020] S7. The biomolecule-functionalized CSUCNPs obtained in step S4 are combined with the biomolecule-functionalized CSUCNPs obtained in step S6 to prepare the upconversion luminescence biosensor.
[0021] Furthermore, the process of step S1 is:
[0022] Yttrium chloride hexahydrate, ytterbium chloride hexahydrate and rare earth element hexahydrate are dissolved in methanol respectively, then oleic acid and 1-octadecene are added, mixed and heated to 150-170°C for 25-35 minutes. After cooling after the reaction, a mixed solution of sodium hydroxide and ammonium fluoride is added dropwise, and the reaction is carried out at 125-135°C for 25-35 minutes, and then the temperature is raised to 290-310°C and maintained for 50-60 minutes. After the reaction is completed, ethanol and ultrapure water are added and centrifuged to obtain upconversion nanoparticle seeds (CUCNPs).
[0023] Furthermore, the total amount of the yttrium chloride hexahydrate, ytterbium chloride hexahydrate and rare earth element hexahydrate is 1-1.5 mmol.
[0024] Furthermore, when the rare earth element is erbium, the ratio of yttrium chloride hexahydrate, ytterbium chloride hexahydrate and rare earth element hexahydrate is 0.78:0.2:0.02.
[0025] Furthermore, when the rare earth element is thulium, the ratio of yttrium chloride hexahydrate, ytterbium chloride hexahydrate and rare earth element hexahydrate is 0.795:0.2:0.005.
[0026] Furthermore, the volume ratio of the methanol, oleic acid and 1-octadecene is 10:(5-7):(14-17).
[0027] Furthermore, the molar ratio of the sodium hydroxide to the ammonium fluoride is 5:(7-9).
[0028] Furthermore, the volume ratio of the ethanol to ultrapure water is 1:(0.6-1).
[0029] Furthermore, the centrifugation parameter is 8000-12000 rpm for 5-10 min.
[0030] Furthermore, the process of step S2 is:
[0031] Yttrium chloride hexahydrate is dissolved in methanol, and then oleic acid and 1-octadecene are added. After mixing, the mixture is heated to 150-170°C and reacted for 25-35 minutes. After cooling, the CUCNPs prepared in step S1 are added, and a mixed solution of sodium hydroxide and ammonium fluoride is added dropwise. The mixture is reacted at 125-135°C for 25-35 minutes, and then the temperature is raised to 290-310°C and maintained for 20-40 minutes. After the reaction is completed, ethanol and ultrapure water are added and centrifuged to obtain core-shell upconversion nanoparticles (CSUCNPs).
[0032] Furthermore, the amount of yttrium chloride hexahydrate used is 0.35-0.45 mmol.
[0033] Furthermore, the volume ratio of the methanol, oleic acid and 1-octadecene is 10:(2.5-3.5):(7-9).
[0034] Furthermore, the molar ratio of the sodium hydroxide to the ammonium fluoride is 2:(2.5-3.5).
[0035] Furthermore, the volume ratio of the ethanol to ultrapure water is 1:(0.6-1).
[0036] Furthermore, the centrifugation parameter is 8000-12000 rpm for 5-10 min.
[0037] Furthermore, the process of step S3 is:
[0038] The CSUCNPs prepared in step S2 were added to a mixed solution of chloroform and toluene, followed by adding a polyacrylic acid aqueous solution and sealing, and vigorously stirring the reaction; after completion, the mixture was washed with ethanol and ultrapure water and centrifuged to obtain hydrophilic polyacrylic acid-modified CSUCNPs (PAA-CSUCNPs).
[0039] Furthermore, the ratio of the CSUCNPs, chloroform, toluene and polyacrylic acid is 50 mg:(2-6 mL):(4-10 mL):(15-20 mL).
[0040] Furthermore, the concentration of the polyacrylic acid aqueous solution is 10-20 mg / mL.
[0041] Furthermore, the stirring reaction time is 24-48h.
[0042] Furthermore, the volume ratio of the ethanol to ultrapure water is 1:(0.6-1).
[0043] Furthermore, the centrifugation parameter is 8000-12000 rpm for 5-10 min.
[0044] Furthermore, the process of step S4 is:
[0045] The PAA-CSUCNPs prepared in step S3 were added to a morpholineethanesulfonic acid buffer solution containing carbodiimide and N-hydroxysulfosuccinimide for the first incubation; after the incubation, the activated PAA-CSUCNPs were obtained by centrifugation and dispersed in a phosphate buffer; a streptavidin solution was added to the solution for a second incubation; after the incubation, the streptavidin-modified CSUCNPs were obtained by centrifugation and dispersed in a phosphate buffer; an EDCs aptamer modified with biotin at the 5' end was then added for a third incubation; after the incubation, the aptamer-modified CSUCNPs were obtained by centrifugation and redispersed in a phosphate buffer; a bovine serum albumin solution was then added for a fourth incubation; after the incubation, the solution was centrifuged and washed with a phosphate buffer to prepare biomolecule-functionalized CSUCNPs.
[0046] Furthermore, the ratio of the PAA-CSUCNPs, carbodiimide, N-hydroxysulfosuccinimide and morpholineethanesulfonic acid buffer solution is (0.8-1.2 mg):4 mg:2 mg:(2.0-2.4 mL).
[0047] Furthermore, the first incubation condition is 20-40° C., 2-4 h.
[0048] Furthermore, the amount of streptavidin used is 0.8-1.2 mg.
[0049] Furthermore, the second incubation condition is 30-40° C., 10-14 h.
[0050] Furthermore, the amount of the aptamer used was 200-300 μL, and the concentration was 10 μM.
[0051] Furthermore, the third incubation condition is 30-40° C., 10-14 h.
[0052] Furthermore, the amount of bovine serum albumin used is 3-6 mL, and the mass fraction is 2%.
[0053] Furthermore, the fourth incubation condition is 30-40° C., 1.5-3 h.
[0054] Furthermore, in step S4, the centrifugal separation parameter is 8000-12000 rpm for 5-10 min.
[0055] Furthermore, in step S4, the pH of the phosphate buffer is 7.2-7.4, and the amount used is 5-15 mL.
[0056] Furthermore, the process of step S5 is:
[0057] Ferric chloride hexahydrate, trisodium citrate dihydrate, and sodium acetate were added to an ethylene glycol solution, stirred vigorously to fully dissolve, and then transferred to a reactor for high-temperature reaction. After the reaction was completed, the prepared magnetic nanoparticles (MNPs) were collected through a magnetic field and washed with ethanol and ultrapure water.
[0058] Furthermore, the ratio of ferric chloride hexahydrate, trisodium citrate dihydrate, sodium acetate and ethylene glycol is 5 mmol:0.4 mmol:(1.2-1.5 g):(15-25 mL).
[0059] Furthermore, the high temperature reaction conditions are 190-210° C., 8-12 h.
[0060] Furthermore, the volume ratio of the ethanol to ultrapure water is 1:(0.6-1).
[0061] Furthermore, the process of step S6 is:
[0062] The MNPs prepared in step S5 are added to a morpholineethanesulfonic acid buffer solution containing carbodiimide and N-hydroxysulfosuccinimide for a first incubation; after the incubation, the activated MNPs are obtained by magnetic separation and dispersed in a phosphate buffer; a streptavidin solution is added to the solution for a second incubation; after the incubation, the streptavidin-modified MNPs are obtained by magnetic separation and dispersed in a phosphate buffer; then, a complementary sequence of an EDCs aptamer modified with biotin at the 5' end is added for a third incubation; after the incubation, the aptamer-modified MNPs are obtained by magnetic separation and redispersed in a phosphate buffer; then, a bovine serum albumin solution is added for a fourth incubation; after the incubation, the MNPs are magnetically separated and washed with a phosphate buffer to prepare biomolecule-functionalized MNPs.
[0063] Furthermore, the ratio of the MNPs, carbodiimide, N-hydroxysulfosuccinimide and morpholineethanesulfonic acid buffer solution is (8-12 mg): 10 mg: 5 mg: (0.8-1.2 mL).
[0064] Furthermore, the first incubation condition is 20-40° C., 2-4 h.
[0065] Furthermore, the amount of streptavidin used is 0.8-1.2 mg.
[0066] Furthermore, the second incubation condition is 30-40° C., 10-14 h.
[0067] Furthermore, the amount of the aptamer complementary sequence used is 200-300 μL, and the concentration is 10 μM.
[0068] Furthermore, the third incubation condition is 30-40° C., 10-14 h.
[0069] Furthermore, the amount of bovine serum albumin used is 3-6 mL, and the mass fraction is 2%.
[0070] Furthermore, the fourth incubation condition is 30-40° C., 1.5-3 h.
[0071] Furthermore, in step S4, the pH of the phosphate buffer solution is 7.2-7.4, and the amount used is 5-15 mL.
[0072] Furthermore, the process of step S7 is:
[0073] The biomolecule-functionalized CSUCNPs prepared in step S4 and the biomolecule-functionalized MNPs prepared in step S6 were added to a phosphate buffer solution and heated at high temperature; after heating, they were slowly annealed and transferred to a shaker for incubation; after incubation, upconversion luminescence biosensors were obtained by magnetic separation, washed three times with phosphate buffer solution, and finally dispersed in phosphate buffer solution.
[0074] Furthermore, the mass ratio of CSUCNPs modified with EDCs aptamers and MNPs modified with EDCs aptamer complementary sequences was (1.5-2):5.
[0075] Furthermore, the high temperature reaction conditions are 90-95° C., 3-5 min.
[0076] Furthermore, the annealing condition is 3-5°C / min, to 60-65°C.
[0077] Furthermore, the incubation conditions are 20-40° C., 0.5-2 h.
[0078] Furthermore, in step 7, the pH of the phosphate buffer solution is 7.2-7.4, and the amount used is 5-10 mL.
[0079] According to the above technical solution, the aptamer-mediated nanoparticle bridging flocculation is used to achieve efficient luminescence enhancement of the upconversion luminescence biosensor. The process is as follows: after the upconversion luminescence biosensor prepared in step S7 is mixed and reacted with the sample solution to be tested, the aptamer specifically binds to EDCs, causing CSUCNPs to fall off from the surface of MNPs; magnetic separation is used to remove the biosensor that has not reacted with the EDCs target, and the CSUCNPs that fall off in the solution reflect the number of target EDCs; the aptamers on the surface of the detached CSUCNPs that are not bound to the target EDCs undergo base complementary pairing, resulting in aptamer-mediated nanoparticle bridging flocculation, which further settles to achieve concentration enrichment of nanoparticles; by optimizing and adjusting the focal length, the signal of the settled CSUCNPs is collected to achieve luminescence enhancement and quantitative detection of EDCs.
[0080] Furthermore, the volume ratio of the upconversion luminescence biosensor prepared in step S7 to the sample solution to be tested is 4:1.
[0081] Furthermore, the focal length of signal acquisition is 11.5 mm.
[0082] Furthermore, the sedimentation time of the detached CSUCNPs was 20–30 min.
[0083] A third object of the present invention is to provide a method for using the above-mentioned microfluidic biosensing platform based on upconversion luminescence, which specifically comprises the following steps:
[0084] A series of EDCs standard solutions with concentrations ranging from 0 to 250 ng / mL were injected into the microfluidic chip together with the prepared upconversion luminescence biosensor to complete the steps of mixing, reacting, separating, and detecting the biosensor and target EDCs.
[0085] The detached CSUCNPs were allowed to stand for completion of bridging flocculation and sedimentation. The fluorescence spectrum of the CSUCNP interface formed by sedimentation in the detection cell was collected using a fluorescence spectrometer. A linear fit was performed between the concentration logarithm of the EDCs standard solution and the characteristic value of the fluorescence signal to establish a standard curve for EDCs content detection; the characteristic value of the fluorescence signal is the characteristic fluorescence emission intensity of the rare earth element used in the biosensor that specifically recognizes EDCs;
[0086] The sample solution to be tested is taken instead of the above-mentioned EDCs standard solution and injected into the microfluidic chip together with the biosensor. The collected fluorescence signal characteristic value is substituted into the standard curve for calculation to obtain the EDCs content in the sample to be tested.
[0087] In summary, the present invention has the following beneficial effects:
[0088] 1. The present invention discloses a novel aptamer-mediated nanoparticle bridging flocculation phenomenon. Based on this discovery, a substantial enhancement of the fluorescence signal of the nanobiosensor is achieved, which greatly improves the sensitivity of target detection and increases the detection limit by at least one order of magnitude. In addition, the aptamer-mediated nanoparticle bridging flocculation forms a stable interface, greatly reducing the influence of the gravity field on the nanoparticle dispersion and effectively improving the signal stability of the nanobiosensor.
[0089] 2. The present invention designs a novel microfluidic chip that integrates 126 semicircular channels and 12 quarter-circular channels in a limited space. This increases the turbulence level of laminar microfluidics with a Reynolds number of approximately 0.79, enabling repeated mixing and reaction between the biosensor and the sample to be tested. With the assistance of an external magnetic field, the mixing, reaction, separation, and detection steps are integrated on the microfluidic chip, greatly improving detection efficiency.
[0090] 3. The present invention prepares an upconversion luminescence microfluidic biosensor. The upconversion luminescence process effectively avoids background fluorescence interference from other matrices. At the same time, the biorecognition element aptamer has good economy and specificity. After further integration into a microfluidic biosensor on the chip, microsampling (30μL) and rapid detection (10min) are achieved, which provides good prospects for actual field applications.
[0091] 4. This invention enables the simultaneous detection of multiple EDCs. A single EDC component below the hazard threshold can pose a serious health hazard when mixed with multiple EDCs, potentially leading to a cumulative effect. By synthesizing multicolor CSUCNPs and modifying them with specific EDC aptamers, this invention fabricated a biosensor for the simultaneous detection of BPA and DES, achieving ultrasensitive detection levels as low as 0.0076 ng / mL and 0.0131 ng / mL, respectively. BRIEF DESCRIPTION OF THE DRAWINGS
[0092] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0093] Figure 1 is a characterization diagram of the prepared nanoparticles; among them, A is a transmission electron microscopy image of CUCNPs doped with erbium; B is a transmission electron microscopy image of CSUCNPs doped with erbium; C is a transmission electron microscopy image of CUCNPs doped with thulium; D is a transmission electron microscopy image of CSUCNPs doped with thulium; E is a transmission electron microscopy image of MNPs; F is a scanning electron microscopy image of MNPs.
[0094] Figure 2 is a characterization diagram of the prepared biosensor; wherein A is a transmission electron microscope image of the biosensor doped with erbium; B is a high-magnification transmission electron microscope characterization of the biosensor doped with erbium, wherein B1 is a high-magnification transmission electron microscope image, and B2-B4 are mapping images of iron and erbium elements, respectively; C is a transmission electron microscope image of the biosensor doped with thulium; D is a high-magnification transmission electron microscope characterization of the biosensor doped with thulium, wherein D1 is a high-magnification transmission electron microscope image, and D2-D4 are mapping images of iron and thulium elements, respectively.
[0095] Figure 3 is a schematic diagram of a microfluidic chip; wherein A is a schematic diagram of the overall structure of the microfluidic chip; B is a diagram of the microchannels of the microfluidic chip, wherein: 1. Sample inlet; 2. Biosensor inlet; 3. Liquid inlet channel; 4. Semicircular channel; 5. Connecting channel; 6. 1 / 4 arc channel; 7. Separation channel; 8. Detection pool.
[0096] Figure 4 is an illustration and characterization of aptamer-mediated nanoparticle bridging flocculation; wherein, A is a schematic diagram of the secondary structure analysis of BPA and DES aptamers and the mediated nanoparticle bridging flocculation; B is a transmission electron microscopy image of aptamer-mediated CSUCNPs bridging flocculation; C is a comparison of the aptamer-mediated CSUCNPs bridging flocculation before and after macroscopic state, wherein C1 is the state without laser excitation, and C2 is the state with 980nm laser excitation.
[0097] Figure 5 is an illustration and characterization of the luminescence enhancement of CSUCNPs; among them, A is the schematic diagram and spectrum of the luminescence enhancement obtained by constructing a core-shell structure at the single-particle level; B is a schematic diagram of the interface formed by aptamer-mediated CSUCNPs bridging flocculation; C is the spectrum of the interface-enhanced luminescence formed by aptamer-mediated CSUCNPs bridging flocculation.
[0098] Figure 6 shows the results of the biosensor detecting EDCs at different concentrations; among them, A is the fluorescence spectrum of detecting EDCs at different concentrations; B is the relationship between the characteristic value of the fluorescence signal at 450nm and the DES concentration; C is the linear fitting curve and equation of the fluorescence characteristic value and the logarithmic value of the EDCs concentration; D is the relationship between the characteristic value of the fluorescence signal at 541nm and the BPA concentration. DETAILED DESCRIPTION
[0099] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the embodiments described are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making any creative efforts shall fall within the scope of protection of the present invention.
[0100] The experimental methods in the following examples, unless otherwise specified, are conventional methods. The experimental materials and reagents used in the following examples, unless otherwise specified, are commercially available. The quantitative experiments in the following examples were performed in triplicate, and the data are presented as the mean or mean ± standard deviation of the three replicates.
[0101] In addition, the "and / or" in the full text includes three solutions. Taking A and / or B as an example, it includes technical solution A, technical solution B, and technical solution that satisfies both A and B. In addition, the technical solutions between the various embodiments can be combined with each other, but it must be based on the ability of ordinary technicians in this field to implement. When the combination of technical solutions is mutually contradictory or cannot be implemented, it should be deemed that such a combination of technical solutions does not exist and is not within the scope of protection required by the present invention.
[0102] Example 1
[0103] In this embodiment, an erbium-doped upconversion luminescence biosensor is prepared, and the upconversion luminescence biosensor is synthesized under nitrogen protection and continuous magnetic stirring.
[0104] The preparation method of the erbium-doped upconversion luminescence biosensor comprises the following steps:
[0105] S1: 0.78 mmol of yttrium chloride hexahydrate, 0.2 mmol of ytterbium chloride hexahydrate, and 0.02 mmol of erbium chloride hexahydrate were dissolved in 10 mL of methanol, followed by the addition of 8 mL of oleic acid and 15 mL of 1-octadecene. The mixture was heated to 150°C for 35 min. After cooling, a mixed solution of 2.5 mmol of sodium hydroxide and 4 mmol of ammonium fluoride was added dropwise, and the mixture was reacted at 125°C for 35 min. The mixture was then heated to 300°C and maintained for 60 min. After the reaction, 10 mL of ethanol and 8 mL of ultrapure water were added, and the mixture was centrifuged at 8500 rpm for 10 min to obtain erbium-doped upconversion nanoparticle seeds (CUCNPs), the transmission electron microscope image of which is shown in Figure 1A.
[0106] S2: 0.4 mmol of yttrium chloride hexahydrate was dissolved in 10 mL of methanol, followed by the addition of 3 mL of oleic acid and 8 mL of 1-octadecene, the mixture was heated to 170°C for 25 min; after the reaction was completed and cooled, the CUCNPs prepared in step S1 were added, and a mixed solution of 1 mmol of sodium hydroxide and 1.5 mmol of ammonium fluoride was added dropwise, and the mixture was reacted at 135°C for 25 min, then heated to 290°C and maintained for 40 min; after the reaction was completed, 10 mL of ethanol and 8 mL of ultrapure water were added, and the mixture was centrifuged at 8500 rpm for 10 min to obtain erbium-doped core-shell upconversion nanoparticles (CSUCNPs), the transmission electron microscope image of which is shown in Figure 1B.
[0107] S3: Take 50 mg of the CSUCNPs prepared in step S2, add them to a mixed solution of 4 mL of chloroform and 6 mL of toluene, then add 20 mL of a 10 mg / mL polyacrylic acid aqueous solution and seal it. Stir vigorously and react at room temperature for 48 hours. After completion, wash with 10 mL of ethanol and 10 mL of ultrapure water, and centrifuge at 9000 rpm for 8 minutes to obtain hydrophilic polyacrylic acid-modified CSUCNPs (PAA-CSUCNPs).
[0108] S4: 5 mg of PAA-CSUCNPs prepared in step S3 were added to a morpholineethanesulfonic acid buffer solution (10 mL) containing 20 mg of carbodiimide and 10 mg of N-hydroxysulfosuccinimide, and incubated at 25°C for 3 h; after the incubation, the activated PAA-CSUCNPs were obtained by centrifugation at 8000 rpm for 10 min, and the PAA-CSUCNPs were dispersed in 10 mL of phosphate buffer (pH 7.2); 1 mL of 1 mg / mL streptavidin solution was added to the solution, and the solution was incubated at 37°C for 12 h; after the incubation, the streptavidin-modified CSUCNPs were obtained by centrifugation at 8500 rpm for 6 min, and the streptavidin-modified CSUCNPs were dispersed in 10 mL of phosphate buffer (pH 7.2); 200 μL 10 μM of a 5'-end biotin-modified BPA aptamer was added and incubated at 37°C for 12 hours. After the incubation, the 5'-end biotin-modified CSUCNPs were obtained by centrifugation at 9000 rpm for 5 minutes, and the CSUCNPs were redispersed in 10 mL of phosphate buffer (pH 7.2). Subsequently, 5 mL of a 2% bovine serum albumin solution was added, and the mixture was incubated at 37°C for 2 hours. After the incubation, the 5'-end biotin-modified CSUCNPs were centrifuged at 10000 rpm for 5 minutes, and the mixture was washed with 10 mL of phosphate buffer (pH 7.2) to prepare biomolecule-functionalized CSUCNPs. The sequence of the BPA aptamer was 5'-Biotin-CCG GTG GGT GGT CAG GTG GGA TAG CGT TCC GCG TAT GGC CCA GCG CAT CAC GGG TTC GCA CCA-3'.
[0109] S5. 1.3515g of ferric chloride hexahydrate, 0.1178g of trisodium citrate dihydrate, and 1.2g of sodium acetate were added to 20mL of ethylene glycol solution and stirred vigorously for 30 minutes until fully dissolved. The mixture was then transferred to a reactor and reacted at 200°C for 12 hours. After the reaction, the prepared magnetic nanoparticles (MNPs) were collected using a magnetic field and washed with 10mL of ethanol and 10mL of ultrapure water. A transmission electron micrograph of the MNPs is shown in Figure 1E, and a scanning electron micrograph is shown in Figure 1F.
[0110] S6. Take 100 mg of the MNPs prepared in step S5, add them to 20 mL of morpholineethanesulfonic acid buffer solution containing 200 mg of carbodiimide and 100 mg of N-hydroxysulfosuccinimide, and incubate at 25°C for 3 hours; after the incubation, magnetic separation is performed to obtain activated MNPs, and the MNPs are dispersed in 10 mL of phosphate buffer (pH 7.2); 1 mL of 1 mg / mL streptavidin solution is added to the solution, and the solution is incubated at 37°C for 12 hours; after the incubation, magnetic separation is performed to obtain MNPs modified with streptavidin, and the MNPs are dispersed in 10 mL of phosphate buffer (pH 7.2); then 200 μL of 10 μM 5'-end modified biotin-containing BPA aptamer complementary sequence is added, and the solution is incubated at 37°C for 12 hours; after the incubation, magnetic separation is performed to obtain MNPs modified with BPA aptamer complementary sequence, and the MNPs are redispersed in 10 mL of phosphate buffer (pH 7.2); then 5 mL The cells were incubated at 37°C for 2 hours with a 2% bovine serum albumin solution. After incubation, the cells were magnetically separated and washed with 10 mL of phosphate buffer (pH 7.2) to prepare biomolecule-functionalized MNPs. The complementary sequence of the BPA aptamer was 5'-Biotin-TTT TTT TGG TGC GAA CCC GTG ATG-3'.
[0111] S7. Take 400 μL of 0.5 mg / mL biomolecule-functionalized CSUCNPs prepared in step S4 and 500 μL of 1 mg / mL biomolecule-functionalized MNPs prepared in step S6, add them to 1 mL of phosphate buffer, and heat at 95°C for 3 min; after heating, slowly anneal to 65°C, and transfer to a shaker and incubate at 37°C for 1 h; after incubation, magnetic separation is performed to obtain the erbium-doped upconversion luminescent biosensor, and the erbium-doped upconversion luminescent biosensor is washed three times with 10 mL of phosphate buffer, and finally dispersed in 5 mL of phosphate buffer; the transmission electron microscopy image of the erbium-doped upconversion luminescent biosensor is shown in Figure 2A, and the high-magnification transmission electron microscopy image and elemental mapping image are shown in Figure 2B, indicating that the erbium-doped upconversion luminescent biosensor was successfully prepared.
[0112] Example 2
[0113] In this embodiment, a thulium-doped upconversion luminescent biosensor is prepared, and the upconversion luminescent biosensor is synthesized under nitrogen protection and continuous magnetic stirring.
[0114] The preparation method of the up-conversion luminescence biosensor doped with thulium element comprises the following steps:
[0115] S1: Take 0.795mmol yttrium chloride hexahydrate, 0.2mmol ytterbium chloride hexahydrate and 0.005mmol thulium chloride hexahydrate and dissolve them in 10mL methanol. Then add 7mL oleic acid and 14mL 1-octadecene, mix and heat to 170℃ for 25min. After cooling, add a mixed solution of 2.5mmol sodium hydroxide and 4mmol ammonium fluoride dropwise and react at 135℃ for 25min. Then heat to 295℃ and keep for 55min. After the reaction, add 10mL ethanol and 10mL ultrapure water, centrifuge at 9500rpm for 5min to obtain thulium-doped upconversion nanoparticle seeds (CUCNPs). The transmission electron microscope image is shown in Figure 1C.
[0116] S2: 0.45 mmol of yttrium chloride hexahydrate was dissolved in 10 mL of methanol, and then 2.5 mL of oleic acid and 8 mL of 1-octadecene were added, mixed, and heated to 150°C for 35 minutes; after the reaction was completed and cooled, the CUCNPs prepared in step S1 were added, and a mixed solution of 1 mmol of sodium hydroxide and 1.5 mmol of ammonium fluoride was added dropwise, and the mixture was reacted at 125°C for 35 minutes, and then the temperature was raised to 300°C and maintained for 20 minutes; after the reaction was completed, 10 mL of ethanol and 10 mL of ultrapure water were added, and the mixture was centrifuged at 12000 rpm for 4 minutes to obtain thulium-doped core-shell upconversion nanoparticles (CSUCNPs), the transmission electron microscope image of which is shown in Figure 1D.
[0117] S3: 50 mg of the CSUCNPs prepared in step S2 were added to a mixed solution of 4 mL of chloroform and 6 mL of toluene, followed by the addition of 15 mL of a 20 mg / mL polyacrylic acid aqueous solution, which was sealed and vigorously stirred at room temperature for 36 h. After completion, the mixture was washed with 10 mL of ethanol and 6 mL of ultrapure water, and centrifuged at 9500 rpm for 7 min to obtain hydrophilic polyacrylic acid-modified CSUCNPs (PAA-CSUCNPs).
[0118] S4: 5 mg of PAA-CSUCNPs prepared in step S3 were added to 12 mL of morpholineethanesulfonic acid buffer solution containing 20 mg of carbodiimide and 10 mg of N-hydroxysulfosuccinimide, and incubated at 30°C for 2 h; after the incubation, the activated PAA-CSUCNPs were obtained by centrifugation at 9500 rpm for 6 min, and dispersed in 10 mL of phosphate buffer (pH 7.2); 1 mL of 1 mg / mL streptavidin solution was added to the solution, and the solution was incubated at 37°C for 10 h; after the incubation, the streptavidin-modified CSUCNPs were obtained by centrifugation at 11000 rpm for 5 min, and dispersed in 10 mL of phosphate buffer (pH 7.2); 200 μL 10 μM of a 5'-end biotin-modified DES aptamer was added and incubated at 37°C for 13 hours. After the incubation, the CSUCNPs modified with the DES aptamer were obtained by centrifugation at 11,500 rpm for 3 minutes and redispersed in 10 mL of phosphate buffer (pH 7.2). Subsequently, 5 mL of a 2% bovine serum albumin solution was added and the mixture was incubated at 37°C for 2 hours. After the incubation, the CSUCNPs were centrifuged at 10,000 rpm for 5 minutes and washed with 10 mL of phosphate buffer (pH 7.2) to prepare biomolecule-functionalized CSUCNPs. The sequence of the DES aptamer was 5'-Biotin-GCC CTC TGA GGA TGC CGA AAA AGA AAA GAA ATT CTC TGG C-3'.
[0119] S5. Take 1.3515g of ferric chloride hexahydrate, 0.1178g of trisodium citrate dihydrate, and 1.2g of sodium acetate and add them to 25mL of ethylene glycol solution. After vigorous stirring for 30min to fully dissolve, transfer them to a reactor and react at a high temperature of 200℃ for 10h. After the reaction is completed, the prepared magnetic nanoparticles (MNPs) are collected by magnetic field and washed with 10mL of ethanol and 10mL of ultrapure water.
[0120] S6. Take 120 mg of the MNPs prepared in step S5, add them to 20 mL of morpholineethanesulfonic acid buffer solution containing 200 mg of carbodiimide and 100 mg of N-hydroxysulfosuccinimide, and incubate at 30°C for 2 hours; after the incubation, obtain activated MNPs by magnetic separation and disperse them in 10 mL of phosphate buffer (pH 7.2); add 1 mL of 1 mg / mL streptavidin solution to the solution, and incubate at 37°C for 10 hours; after the incubation, obtain MNPs modified with streptavidin by magnetic separation and disperse them in 10 mL of phosphate buffer (pH 7.2); then add 200 μL of 10 μM 5'-end modified biotin DES aptamer complementary sequence, and incubate at 37°C for 13 hours; after the incubation, obtain MNPs modified with DES aptamer complementary sequence by magnetic separation and redisperse them in 10 mL of phosphate buffer (pH 7.2); then add 5 mL 2% bovine serum albumin solution was incubated at 37°C for 3 hours; after incubation, magnetic separation was performed and washed with 10 mL of phosphate buffer (pH 7.2) to prepare biomolecule-functionalized MNPs; wherein the complementary sequence of the DES aptamer is 5'-Biotin-TTTTTT GCC AGA GAA TTT CTT-3'.
[0121] S7. Take 300 μL of 0.5 mg / mL biomolecule-functionalized CSUCNPs prepared in step S4 and 500 μL of 1 mg / mL biomolecule-functionalized MNPs prepared in step S6, add them to 1 mL of phosphate buffer, and heat at 90°C for 5 min; after heating, slowly anneal to 65°C, and transfer to a shaker and incubate at 37°C for 2 h; after incubation, magnetic separation is performed to obtain the thulium-doped upconversion luminescent biosensor, and the thulium-doped upconversion luminescent biosensor is washed three times with 10 mL of phosphate buffer, and finally dispersed in 5 mL of phosphate buffer; the transmission electron microscopy image of the thulium-doped upconversion luminescent biosensor is shown in Figure 2C, and the high-magnification transmission electron microscopy image and element mapping image are shown in Figure 2D, indicating that the thulium-doped upconversion luminescent biosensor was successfully prepared.
[0122] Example 3
[0123] The microfluidic chip prepared by soft lithography has a structure as shown in Figures 3A and 3B, including a sample inlet 1 and a biosensor inlet 2. The cross-sections of the sample inlet 1 and the biosensor inlet 2 are circular with a diameter of 8 mm and a depth of 1 cm.
[0124] The sample inlet 1 and the biosensor inlet 2 are respectively connected with a liquid inlet channel 3 , and the other ends of the two liquid inlet channels 3 intersect and connect with each other, with an included angle of 90°. The two liquid inlet channels 3 are 9 mm long.
[0125] The microfluidic chip also includes a semicircular channel 4 and a quarter-circular arc channel 6, and the connections between the channels are tangentially connected to achieve a smooth transition of the microfluid within the microchannel; the microfluidic chip also includes a connecting channel 5, the two ends of the connecting channel 5 are tangentially connected to the semicircular channel 4 and the quarter-circular arc channel 6, respectively, to change the direction of the arc channel.
[0126] 126 semicircular channels 4 (with a radius of 800 μm), 25 1 / 4 arc channels 6 (with a radius of 800 μm), and 11 connecting channels 5 (with a length of 500 μm) constitute the arc channel as shown in Figure 3B in this embodiment. The feed port of the arc channel is connected to the intersection of the two liquid inlet channels 3, and the discharge port is connected to the separation channel 7. The separation channel 7 is a straight channel with a length of 6.8 mm. The other end of the separation channel 7 is connected to a detection pool 8, which is used for magnetic separation of the biosensor. The detection pool 8 has a diameter of 1.2 cm and a depth of 1 cm. It is used for bridging flocculation, sedimentation, and fluorescence signal collection of detached CSUCNPs; in this embodiment, the width of all channels is 400 μm and the depth is 200 μm.
[0127] Aptamer-mediated nanoparticle bridging flocculation and luminescence enhancement, including the following steps:
[0128] In Example 1 and Example 2, core-shell CSUCNPs were prepared, respectively, and the first luminescence enhancement was achieved at the single nanoparticle level, as shown in FIG5A . Among them, the CSUCNPs doped with erbium achieved a 1.72-fold luminescence enhancement, and the CSUCNPs doped with thulium achieved a 2.28-fold luminescence enhancement. The secondary structure prediction of DES and BPA aptamers is shown in FIG4A , which shows the presence of a stem-loop structure, indicating that the aptamer sequence contains complementary paired base sequences and can stably hybridize, thereby causing the CSUCNPs modified with the aptamer sequence to bind to each other to form bridged flocculation, as shown in FIG4A ; aptamer-mediated The microscopic transmission electron microscopy image of CSUCNPs bridge flocculation is shown in Figure 4B. It can be clearly observed that CSUCNPs are agglomerated into nanoaggregates from dispersed single nanoparticles (Figures 1A-1D); this allows the surface biomolecule-functionalized CSUCNPs to settle from a dispersed solution state to form an interface (Figures 4C and 5B) from a macroscopic perspective, and adjust the fluorescence signal acquisition method to be parallel to the direction of the gravitational field (Figure 4C2) to achieve luminescence enhancement at the nanoparticle group level. As shown in Figure 5C, the luminescence of the biosensor doped with erbium was enhanced by 7.10 times, and the luminescence of the biosensor doped with thulium was enhanced by 8.94 times.
[0129] Example 4
[0130] The upconversion luminescence-based biosensor realizes the simultaneous detection of BPA and DES, including the following steps:
[0131] A. Equal volumes of the upconversion luminescence biosensors prepared in Example 1 and Example 2 were mixed uniformly to form a mixed biosensor solution that could simultaneously recognize BPA and DES. The test sample solution and the mixed biosensor solution were then injected into the sample inlet 1 and biosensor inlet 2 of the microfluidic chip, respectively, at injection flow rates of 12 μL / min and 3 μL / min, respectively, for a time of 10 minutes. The two microfluids were fully mixed and reacted within the microchannel of the microfluidic chip. Simultaneously, an external magnetic field was applied to the separation channel 7 to separate the biosensors that did not react with BPA and DES. The mixed liquid then entered the detection cell 8, where the detached CSUCNPs completed bridging flocculation and sedimentation. The sedimentation took 20 minutes to reach a steady state, completing the collection of the upconversion fluorescence signal.
[0132] B. A series of BPA and DES mixed standard solutions with concentrations ranging from 0 to 250 ng / mL were injected together with the prepared upconversion luminescence biosensor into the microfluidic chip according to step S1 to complete the mixing, reaction, separation and detection steps of the biosensor and the target EDCs. The upconversion fluorescence spectra collected by the detection of the mixed standard solutions with different concentrations are shown in Figure 6A. With the increase of BPA and DES concentrations, the fluorescence intensity at 541 nm and 450 nm gradually increased. The characteristic value of the fluorescence signal at 450 nm, I 450 The relationship between the fluorescence signal characteristic value I at 541 nm and the DES concentration is shown in FIG6B . 541 The relationship between the concentration of BPA and the concentration of β-glutamic acid is shown in Figure 6D.
[0133] C. Fit the characteristic value of the fluorescence signal with the concentration of the target EDCs to obtain the linear mathematical formula for detection, as shown in Figure 6C. The standard curve fitting for BPA detection is y1=0.2475x1+0.4337, R 2 =0.9962, the detection range is 0.025-100 ng / mL, and the detection limit is 0.0076 ng / mL, where x1 is the logarithmic value of BPA concentration, and y1 is the characteristic value of the fluorescence signal at 450 nm. 450 The normalized fluorescence intensity of the DES test was fitted with a standard curve of y2 = 0.1267x2 + 0.2432, R 2 =0.9958, the detection range is 0.025-250 ng / mL, and the detection limit is 0.0131 ng / mL, where x2 is the logarithmic value of the DES concentration, and y2 is the characteristic value of the fluorescence signal at 541 nm. 541 The normalized fluorescence intensity.
[0134] Application Example 1
[0135] In this embodiment, the sample to be tested is seawater.
[0136] Original seawater samples were collected from the coast of the sea area, centrifuged at 4000 rpm for 10 min, and the supernatant was retained. The seawater supernatant was further filtered with a 0.45 μm filter membrane to remove impurities and used for detection.
[0137] The upconversion luminescence microfluidic biosensor platform was used for detection, and the characteristic value of the fluorescence signal I was measured. 450 and the fluorescence signal characteristic value I 541 The values were 0.3592 and 0.6720 respectively. Substituting them into the standard curve, the DES and BPA contents in the seawater samples were 8.24 ng / mL and 9.18 ng / mL respectively.
[0138] To verify the accuracy of the detection method of the present invention, the same experimental samples were measured using gas chromatography-mass spectrometry (GC-MS) in accordance with the provisions of the Chinese national standard GB31660.2-2019. The BPA detection standard curve established by GC-MS is y3=721.83x3-6218.20, R 2 =0.9947, where x3 is the BPA concentration and y3 is the peak area corresponding to the BPA characteristic peak; the DES detection standard curve is y4=372.07x4-2004.95, R 2 =0.9953, where x4 is the DES concentration and y4 is the peak area corresponding to the DES characteristic peak.
[0139] The GC-MS method was used for detection, and the peak areas corresponding to the characteristic peaks of DES and BPA were 5585 and 7575, respectively. The DES and BPA contents in the seawater samples were calculated to be 8.16 ng / mL and 7.64 ng / mL, respectively, by substituting them into the standard curve.
[0140] Application Example 2
[0141] In this embodiment, the sample to be tested is shrimp.
[0142] A 5g edible portion of fresh supermarket shrimp samples was homogenized and randomly spiked with unknown concentrations of DES and BPA standard solutions. The shrimp samples were placed in a 50mL centrifuge tube, mixed by vortexing, and ultrasonically extracted for 10 minutes. The sample was then centrifuged at 4000 r / min for 10 minutes, and the supernatant was transferred to a 100mL pear-shaped flask. The residue was repeatedly extracted with 10mL of ethyl acetate. The supernatants from the two centrifugations were combined and rotary evaporated to dryness at 40°C. The residue was dissolved in 5mL of a 50% by volume cyclohexane-ethyl acetate solution, and DES and BPA were extracted using a 60mg / mL solid-phase extraction column. The eluent from the solid-phase extraction column was used for detection.
[0143] The upconversion luminescence microfluidic biosensor platform was used for detection, and the characteristic value of the fluorescence signal I was measured. 450 and the fluorescence signal characteristic value I 541 The values were 0.3535 and 0.6801 respectively. Substituting them into the standard curve, the DES and BPA contents in the shrimp samples were 7.42 ng / mL and 9.90 ng / mL respectively.
[0144] The GC-MS method was used for detection, and the peak areas corresponding to the characteristic peaks of DES and BPA were 5315 and 11480, respectively. The DES and BPA contents in the shrimp samples were calculated to be 7.79 ng / mL and 9.71 ng / mL, respectively.
[0145] Application Example 3
[0146] In this embodiment, the sample to be tested is fish meat.
[0147] A 5g edible portion of fresh fish samples purchased from a supermarket was homogenized and randomly spiked with DES and BPA standard solutions of unknown concentrations. The fish samples were placed in a 50mL centrifuge tube, mixed with 3mL of sodium carbonate solution and 20mL of ethyl acetate, and ultrasonically extracted for 10 minutes. The sample was then centrifuged at 4000r / min for 10 minutes, and the supernatant was transferred to a 100mL pear-shaped flask. The residue was repeatedly extracted with 10mL of ethyl acetate. The supernatants from the two centrifugations were combined and rotary evaporated to dryness at 40°C. The residue was dissolved in 5mL of a 50% by volume cyclohexane-ethyl acetate solution, and DES and BPA were extracted using a 60mg / mL solid-phase extraction column. The eluent from the solid-phase extraction column was used for detection.
[0148] The upconversion luminescence microfluidic biosensor platform was used for detection, and the characteristic value of the fluorescence signal I was measured. 450 and the fluorescence signal characteristic value I 541 The values were 0.4462 and 0.6749 respectively. Substituting them into the standard curve, the DES and BPA contents in the fish samples were 40.00 ng / mL and 9.43 ng / mL respectively.
[0149] Using the GC-MS method for detection, the peak areas corresponding to the characteristic peaks of DES and BPA were measured to be 31959 and 10527, respectively. Substituting the standard curve into the calculated values, the DES and BPA contents in the fish samples were 36.01 ng / mL and 9.15 ng / mL, respectively.
[0150] The technical features of the above-mentioned embodiments can be combined arbitrarily. In order to make the description concise, not all possible combinations of the technical features in the above-mentioned embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0151] The above-described embodiments merely illustrate several implementations of the present invention, and while their descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the patent. It should be noted that a person skilled in the art would be able to make numerous variations and improvements without departing from the spirit of the present invention, all of which fall within the scope of protection of the present invention. Therefore, the scope of protection of the patent for this invention shall be determined by the appended claims.
Claims
1. A microfluidic biosensing platform based on upconversion luminescence, It is characterized in that include: Upconversion luminescence biosensors for specific recognition of EDCs; and a microfluidic chip, serving as a reaction platform between the upconversion luminescent biosensor and the sample to be tested, for integrating the mixing, reaction, separation, and detection of the upconversion luminescent biosensor and the sample to be tested; The microfluidic chip comprises: a sample injection pool for injecting the upconversion luminescent biosensor and the sample to be tested; An arc-shaped channel, wherein the feed port of the arc-shaped channel is simultaneously connected to the sample injection pool of the upconversion luminescence biosensor and the sample injection pool of the sample to be tested, and after the upconversion luminescence biosensor and the sample to be tested enter the arc-shaped channel, the arc-shaped channel is used for mixing and reacting the two; a separation channel, connected to the discharge port of the arc-shaped channel, is used for magnetic separation of the upconversion luminescence biosensor after the reaction is completed; and a detection pool, connected to the discharge port of the separation channel, is used to complete luminescence enhanced quantitative detection of EDCs.
2. A method for preparing the upconversion luminescence biosensor according to claim 1, It is characterized in that The preparation method of the upconversion luminescence biosensor comprises the following steps: S1. Preparation of upconversion nanoparticle seeds (CUCNPs) containing rare earth elements; S2, coating the outer layer of the CUCNPs prepared in step S1 to prepare upconversion nanoparticles (CSUCNPs) with a core-shell structure; S3, the CSUCNPs prepared in the modification step S2 are hydrophilic; S4, functionalizing the hydrophilic CSUCNPs obtained in step S3 with biomolecules to obtain biomolecule-functionalized CSUCNPs; S5. preparing magnetic nanoparticles (MNPs); S6, functionalizing the MNPs obtained in step S5 with biomolecules to obtain biomolecule-functionalized MNPs; S7. The biomolecule functionalized CSUCNPs obtained in step S4 are combined with the biomolecule functionalized CSUCNPs obtained in step S6 to prepare the upconversion luminescent biosensor.
3. The method for preparing the upconversion luminescence biosensor according to claim 2, Features: The process of step S1 is: Yttrium chloride hexahydrate, ytterbium chloride hexahydrate and rare earth element hexahydrate are dissolved in methanol respectively, and then oleic acid and 1-octadecene are added, mixed and heated to 150-170°C for reaction for 25-35 minutes, and after cooling after the reaction, a mixed solution of sodium hydroxide and ammonium fluoride is added dropwise, and reacted at 125-135°C for 25-35 minutes, and then heated to 290-310°C for 50-60 minutes; after the reaction is completed, ethanol and ultrapure water are added and centrifuged to obtain upconversion nanoparticle seeds (CUCNPs); When the rare earth element is erbium, the ratio of yttrium chloride hexahydrate, ytterbium chloride hexahydrate and the rare earth element hexahydrate is: 0.78:0.2:0.02; or When the rare earth element is thulium, the ratio of yttrium chloride hexahydrate, ytterbium chloride hexahydrate and the rare earth element hexahydrate is 0.795:0.2:0.
005.
4. The method for preparing the upconversion luminescence biosensor according to claim 2, Features: The process of step S2 is: Yttrium chloride hexahydrate is dissolved in methanol, and then oleic acid and 1-octadecene are added, mixed and heated to 150-170°C for reaction for 25-35 minutes; after the reaction is completed and cooled, the CUCNPs prepared in step S1 are added, and a mixed solution of sodium hydroxide and ammonium fluoride is added dropwise, and reacted at 125-135°C for 25-35 minutes, and then the temperature is raised to 290-310°C and maintained for 20-40 minutes; after the reaction is completed, ethanol and ultrapure water are added and centrifuged to obtain core-shell upconversion nanoparticles (CSUCNPs).
5. The method for preparing the upconversion luminescence biosensor according to claim 2, Features: The process of step S3 is: The CSUCNPs prepared in step S2 were added to a mixed solution of chloroform and toluene, and then a polyacrylic acid aqueous solution was added and sealed, and the reaction was vigorously stirred; after completion, ethanol and ultrapure water were used to wash and centrifuge to obtain hydrophilic polyacrylic acid-modified CSUCNPs (PAA-CSUCNPs).
6. The method for preparing the upconversion luminescence biosensor according to claim 2, Features: The process of step S4 is: The PAA-CSUCNPs prepared in step S3 are added to a morpholineethanesulfonic acid buffer solution containing carbodiimide and N-hydroxysulfosuccinimide for the first incubation; after the incubation, the activated PAA-CSUCNPs are obtained by centrifugation and dispersed in a phosphate buffer; Add streptavidin solution to the solution for a second incubation; After the incubation, the streptavidin-modified CSUCNPs were obtained by centrifugation and dispersed in a phosphate buffer; then, an EDCs aptamer modified with biotin at the 5' end was added for a third incubation; after the incubation, the aptamer-modified CSUCNPs were obtained by centrifugation and redispersed in a phosphate buffer; then, a bovine serum albumin solution was added for a fourth incubation; after the incubation, the CSUCNPs were centrifuged and washed with a phosphate buffer to prepare biomolecule-functionalized CSUCNPs.
7. The method for preparing the upconversion luminescence biosensor according to claim 2, Features: The process of step S5 is: Ferric chloride hexahydrate, trisodium citrate dihydrate, and sodium acetate were respectively added to ethylene glycol solution, stirred vigorously to fully dissolve, and then transferred to a reactor for high-temperature reaction; after the reaction was completed, the prepared magnetic nanoparticles (MNPs) were collected through a magnetic field and washed with ethanol and ultrapure water.
8. The method for preparing the upconversion luminescence biosensor according to claim 2, Features: The process of step S6 is: The MNPs prepared in step S5 are added to a morpholineethanesulfonic acid buffer solution containing carbodiimide and N-hydroxysulfosuccinimide for the first incubation; after the incubation, the activated MNPs are obtained by magnetic separation and dispersed in a phosphate buffer; a streptavidin solution is added to the solution for a second incubation; after the incubation, the MNPs modified with streptavidin are obtained by magnetic separation and dispersed in a phosphate buffer; then, a complementary sequence of an EDCs aptamer modified with biotin at the 5' end is added for a third incubation; after the incubation, the aptamer-modified MNPs are obtained by magnetic separation and redispersed in a phosphate buffer; then, a bovine serum albumin solution is added for a fourth incubation; after the incubation, the MNPs are magnetically separated and washed with a phosphate buffer to prepare biomolecule-functionalized MNPs.
9. The method for preparing the upconversion luminescence biosensor according to claim 2, Features: The process of step S7 is: The CSUCNPs modified with the EDCs aptamer prepared in step S4 and the MNPs modified with the EDCs aptamer complementary sequence prepared in step S6 were added to a phosphate buffer and heated at high temperature; after heating, they were slowly annealed and transferred to a shaker for incubation; after incubation, upconversion luminescent biosensors were obtained by magnetic separation, washed three times with a phosphate buffer, and finally dispersed in a phosphate buffer.
10. A method for using the microfluidic biosensing platform based on upconversion luminescence as claimed in claim 1, It is characterized in that The specific steps include: A series of EDCs standard solutions with concentrations ranging from 0 to 250 ng / mL are taken and co-injected with the prepared upconversion luminescent biosensor into the microfluidic chip to complete the steps of mixing, reacting, separating and detecting the biosensor and the target EDCs; The CSUCNPs were allowed to stand to complete the bridge flocculation and sedimentation of the detached CSUCNPs, and the fluorescence spectrum of the CSUCNPs interface formed by the sedimentation in the detection pool was collected by a fluorescence spectrometer. The concentration logarithm of the EDCs standard solution and the characteristic value of the fluorescence signal were linearly fitted to establish a standard curve for EDCs content detection; the characteristic value of the fluorescence signal was the characteristic fluorescence emission intensity of the rare earth element used in the biosensor that specifically identified EDCs; The sample solution to be tested is taken to replace the above EDCs standard solution and is injected into the microfluidic chip together with the biosensor. The characteristic value of the collected fluorescence signal is substituted into the standard curve for calculation to obtain the content of EDCs in the sample to be tested.
Citation Information
Patent Citations
Nucleic acid detection method and kit
CN106062210A
Micro-fluidic magneto-sensitive immune device based on magnetoresistive biosensor and using method thereof
CN110632168A
Fluorescent sensor for simultaneously detecting staphylococcus aureus enterotoxins A and B based on aptamer recognition-hybrid chain reaction
CN111139288A
Microfluidic magnetic relaxation sensing detection method based on self-assembly of nano-particles regulated and controlled by enzyme
CN113514488A
Integrated seminal fluid analysis system and method
CN115266675A
